Clinical trials: Chronic Kidney Disease Stage 2
End-Stage Renal Disease
L-Carnitine in Peritoneal Dialysis
The development of glucose-sparing strategies able to provide an efficacious ultrafiltration profile represents one of the modern goals of peritoneal dialysis therapy.
- Trial name
- NCT00922701
- Testing
- L-carnitine
- Where
- Italy
- Volunteers
- 4 people
- Sponsor
- Iperboreal Pharma Srl
Chronic Kidney Disease
Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients
The purpose of this study is to demonstrate equivalence of calcium acetate oral solution and sevelamer carbonate in maintaining serum phosphorus levels This is a phase IV, multicenter, randomized, open-label, cross-over study to…
- Trial name
- COS-002 (NCT01427907)
- Testing
- Calcium acetate oral solution (COS), Sevelamer carbonate
- Where
- 4 sites in United States
- Volunteers
- 38 people
- Sponsor
- Fresenius Medical Care North America
Chronic Kidney Disease, Dialysis
A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia
This is a phase III multi-centre study in two periods: the first period is a phosphate binder and lipid lowering drugs washout for 8 weeks, the second period is a double-blind, randomised, parallel group, fixed dose, for 12 weeks.
- Conditions
- Chronic Kidney Disease, Dialysis, Hyperphosphatemia, Dyslipidemia
- Trial name
- NCT00542386
- Testing
- MCI-196
- Where
- 73 sites in Hungary, Italy and 6 more
- Volunteers
- 642 people
- Sponsor
- Tanabe Pharma Corporation
Chronic Kidney Disease
A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia
The objective of this study is to evaluate the efficacy and the safety when ASP1517 is intermittently administered in Erythropoiesis Stimulating Agent (ESA)-untreated non-dialysis chronic kidney disease patients with anemia.
- Trial name
- NCT02964936
- Testing
- roxadustat
- Where
- 38 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Astellas Pharma Inc
Kidney Failure, Chronic
A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis
This is a multi-center, two-part study; Part A and Part B. Part A of the study is an open-label, single-dose pharmacokinetic (PK) evaluation of 100 mg RVX000222 on dialysis and non-dialysis days in eight (8) End Stage Renal…
- Trial name
- NCT03160430
- Testing
- apabetalone
- Volunteers
- 44 people
- Sponsor
- Resverlogix Corp
Type 2 Diabetes Mellitus, Chronic Kidney Disease
A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes
Finerenone works by blocking a group of proteins, called mineralocorticoid receptor. An increased stimulation of mineralocorticoid receptor is known to trigger injury and inflammation in the kidney and is therefore thought to…
- Trial name
- CONFIDENCE (NCT05254002)
- Testing
- Finerenone (BAY94-8862 ) 10 mg, Empagliflozin, Finerenone (BAY94-8862 ) 20 mg
- Where
- 173 sites in United States, Belgium and 12 more
- Volunteers
- 1,664 people
- Sponsor
- Bayer
Chronic Kidney Diseases
CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)
CLBS201 will evaluate the safety, tolerability, and therapeutic effect in subjects with CKD and T2DM.
- Trial name
- NCT04990427
- Testing
- CLBS201
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Lisata Therapeutics, Inc.
Type 2 Diabetes Mellitus, Chronic Kidney Diseases
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
The purpose of this study is to assess the safety and efficacy of up to 2 REACT/rilparencel injections in participants with T2DM and CKD.
- Trial name
- NCT05099770
- Testing
- Renal Autologous Cell Therapy (REACT/ rilparencel)
- Where
- 88 sites in United States, Mexico and 2 more
- Volunteers
- 685 people
- Sponsor
- Prokidney
Chronic Kidney Disease
Paricalcitol Injection Phase II Trial
The PK and tolerability of paricalcitol after repeated intravenous administration for 2 weeks (total 6 doses at every HD session) are studied in subjects with 2°HPT who are receiving HD 3 times a week for stable chronic renal…
- Trial name
- NCT00646932
- Testing
- paricalcitol
- Where
- 10 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Abbott
Type 2 Diabetes, Obesity
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk.
- Conditions
- Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight
- Trial name
- ACHIEVE-4 (NCT05803421)
- Testing
- Orforglipron, Insulin Glargine
- Where
- 358 sites in United States, Argentina and 14 more
- Volunteers
- 2,749 people
- Sponsor
- Eli Lilly and Company
End Stage Renal Disease Requiring Hemodialysis
Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug
Patients whose kidneys are no longer able to work as they should and require treatment to filter wastes from the blood (hemodialysis) are at high risk for blood clots that form in blood vessels (thrombosis) blocking blood flow…
- Trial name
- RE-THINc ESRD (NCT04534114)
- Testing
- Fesomersen sodium (BAY2976217)
- Where
- 69 sites in United States, Belgium and 13 more
- Volunteers
- 307 people
- Sponsor
- Bayer
Chronic Kidney Disease With High Proteinuria
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
This is a Phase III, randomised, multicentre, double-blinded study to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney disease (CKD)…
- Trial name
- NCT06087835
- Testing
- Zibotentan/Dapagliflozin, Dapagliflozin
- Where
- 296 sites in United States, Argentina and 28 more
- Volunteers
- 1,835 people
- Sponsor
- AstraZeneca